Trial Search Results

A Study of an Investigational V212/Heat-Treated VZV Vaccine in Immunocompromised Adults (V212-002)(COMPLETED)

The proposed indication for the investigational heat-treated varicella-zoster virus (VZV) vaccine is the prevention of herpes zoster (HZ) and HZ-related complications in immunocompromised individuals.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Merck Sharp & Dohme Corp.

Stanford Investigator(s):


  • Biological: Comparator: V212
  • Biological: Comparator: Placebo


Phase 1


Inclusion Criteria:

   - Men and women > or = to 18 years of age who are scheduled to receive an autologous or
   allogeneic hematopoietic cell transplant within 60 days of enrollment

   - HIV-infected patients with a baseline CD4 cell count < or = to 200 cells/mm^3

   - Patients with hematologic malignancies; or patients who are receiving chemotherapy for
   breast, colorectal, lung, or ovarian malignancies

Exclusion Criteria:

   - History of allergy to any vaccine component

   - Prior history of HZ

   - Prior history of receipt of any varicella or zoster vaccine

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Dora Ho
Not Recruiting